Withdraws plans March 29 to offer up to 20% of its common stock in three separate "unbundled" financial pieces. Firm said it made decision "on the recommendation of Shearson Lehman Hutton . . . after [Pfizer] was notified by the SEC that the [unbundled stock units] would be treated as outstanding shares in determining earnings per share contrary to the advice we had received concerning precedent and current accounting standards".
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.